4. Inhibition of Cyclin-Dependent Kinases 4/6 (CDK4/6) as a Source of Therapeutic Targets in Pediatric and AYA Sarcomas Based on Precision Genomics/Transcriptomics Profiling. This evidence concerns the gene CDK4 and sarcoma.